{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:09:03Z","timestamp":1740460143205,"version":"3.37.3"},"reference-count":109,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,1,12]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>The European Respiratory Society International Congress 2021 took place virtually for the second year running due to the coronavirus pandemic. The Congress programme featured more than 400 sessions and 3000 abstract presentations, covering the entire field of respiratory science and medicine. In this article, early career members of the Respiratory Infections Assembly summarise a selection of sessions across a broad range of topics, including presentations on bronchiectasis, non-tuberculosis mycobacteria, tuberculosis, cystic fibrosis and COVID-19.<\/jats:p>","DOI":"10.1183\/23120541.00642-2021","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T18:05:26Z","timestamp":1643911526000},"page":"00642-2021","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["ERS International Congress 2021: highlights from the Respiratory Infections Assembly"],"prefix":"10.1183","volume":"8","author":[{"given":"Oliver W.","family":"Meldrum","sequence":"first","affiliation":[]},{"given":"Kylie B.R.","family":"Belchamber","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7403-636X","authenticated-orcid":false,"given":"Kiarina D.","family":"Chichirelo-Konstantynovych","sequence":"additional","affiliation":[]},{"given":"Katie L.","family":"Horton","sequence":"additional","affiliation":[]},{"given":"Tetyana V.","family":"Konstantynovych","sequence":"additional","affiliation":[]},{"given":"Merete B.","family":"Long","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5721-5710","authenticated-orcid":false,"given":"Melissa J.","family":"McDonnell","sequence":"additional","affiliation":[]},{"given":"Lidia","family":"Perea","sequence":"additional","affiliation":[]},{"given":"Alberto L.","family":"Garcia-Basteiro","sequence":"additional","affiliation":[]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-701X","authenticated-orcid":false,"given":"Holly R.","family":"Keir","sequence":"additional","affiliation":[]}],"member":"81","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2024101711285632000_8.2.00642-2021.1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0108-2018"},{"key":"2024101711285632000_8.2.00642-2021.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01289-7"},{"key":"2024101711285632000_8.2.00642-2021.3","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101711285632000_8.2.00642-2021.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00453-2020"},{"key":"2024101711285632000_8.2.00642-2021.5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13756-020-00783-w","article-title":"Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin","volume":"9","author":"Djamin","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2024101711285632000_8.2.00642-2021.6","doi-asserted-by":"crossref","first-page":"1753466620936866","DOI":"10.1177\/1753466620936866","article-title":"Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis","volume":"14","author":"Xu","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"2024101711285632000_8.2.00642-2021.7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/crj.13116","article-title":"Clinical characteristics and outcomes of patients with Escherichia coli in airway samples","volume":"14","author":"Schneer","year":"2020","journal-title":"Clin Respir J"},{"key":"2024101711285632000_8.2.00642-2021.8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024101711285632000_8.2.00642-2021.9","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S1473-3099(20)30327-3","article-title":"The value of antimicrobial peptides in the age of resistance","volume":"20","author":"Magana","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024101711285632000_8.2.00642-2021.10","doi-asserted-by":"crossref","first-page":"e0226507","DOI":"10.1371\/journal.pone.0226507","article-title":"Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis","volume":"14","author":"Chaves Torres","year":"2019","journal-title":"PLoS One"},{"key":"2024101711285632000_8.2.00642-2021.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"2024101711285632000_8.2.00642-2021.12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00134-019-05519-y","article-title":"Challenges in severe community-acquired pneumonia: a point-of-view review","volume":"45","author":"Torres","year":"2019","journal-title":"Intensive Care Med"},{"key":"2024101711285632000_8.2.00642-2021.13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","article-title":"Effect of combined \u03b2-lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia","volume":"155","author":"Ceccato","year":"2019","journal-title":"Chest"},{"key":"2024101711285632000_8.2.00642-2021.14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.15","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101711285632000_8.2.00642-2021.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00769-2020"},{"key":"2024101711285632000_8.2.00642-2021.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2024101711285632000_8.2.00642-2021.18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent advances in severe asthma: from phenotypes to personalized medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest"},{"key":"2024101711285632000_8.2.00642-2021.19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S2213-2600(18)30510-1","article-title":"Functional effects of the microbiota in chronic respiratory disease","volume":"7","author":"Budden","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-2600(20)30557-9","article-title":"The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study","volume":"9","author":"Dicker","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02050-2020"},{"key":"2024101711285632000_8.2.00642-2021.22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.009"},{"key":"2024101711285632000_8.2.00642-2021.24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5414\/CP201674","article-title":"Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD","volume":"51","author":"Gunawardena","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2024101711285632000_8.2.00642-2021.25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.103440"},{"key":"2024101711285632000_8.2.00642-2021.26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcf.2015.10.008","article-title":"A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation","volume":"15","author":"Chillappagari","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2024101711285632000_8.2.00642-2021.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00048-2021"},{"key":"2024101711285632000_8.2.00642-2021.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2020.2350"},{"key":"2024101711285632000_8.2.00642-2021.29","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00081-2015"},{"key":"2024101711285632000_8.2.00642-2021.30","doi-asserted-by":"crossref","unstructured":"Polverino E , Goeminne PC , McDonnell MJ , et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629. doi:10.1183\/13993003.00629-2017","DOI":"10.1183\/13993003.00629-2017"},{"key":"2024101711285632000_8.2.00642-2021.31","doi-asserted-by":"crossref","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","article-title":"Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry","volume":"7","author":"Dhar","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2024101711285632000_8.2.00642-2021.32","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/jcm8091461","article-title":"Effect of corticosteroids on c-reactive protein in patients with severe community-acquired pneumonia and high inflammatory response: the effect of lymphopenia","volume":"8","author":"Torres","year":"2019","journal-title":"J Clin Med"},{"key":"2024101711285632000_8.2.00642-2021.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01183-2018"},{"key":"2024101711285632000_8.2.00642-2021.34","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"2024101711285632000_8.2.00642-2021.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00148-2015"},{"key":"2024101711285632000_8.2.00642-2021.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.12.009"},{"key":"2024101711285632000_8.2.00642-2021.37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2024101711285632000_8.2.00642-2021.39","doi-asserted-by":"publisher","DOI":"10.1111\/all.14532"},{"key":"2024101711285632000_8.2.00642-2021.40","doi-asserted-by":"crossref","unstructured":"Perkins GD , Ji C , Connolly BA , et al. An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19. medRxiv 2021; preprint [https:\/\/doi.org\/10.1101\/2021.08.02.21261379].","DOI":"10.1101\/2021.08.02.21261379"},{"key":"2024101711285632000_8.2.00642-2021.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1985"},{"key":"2024101711285632000_8.2.00642-2021.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z"},{"key":"2024101711285632000_8.2.00642-2021.43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13643-020-01363-0","article-title":"Noninvasive oxygenation strategies in adult patients with acute respiratory failure: a protocol for a systematic review and network meta-analysis","volume":"9","author":"Ferreyro","year":"2020","journal-title":"Syst Rev"},{"key":"2024101711285632000_8.2.00642-2021.44","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04617-3"},{"key":"2024101711285632000_8.2.00642-2021.45","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S2213-2600(21)00286-1","article-title":"The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease","volume":"9","author":"Adeloye","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2316"},{"key":"2024101711285632000_8.2.00642-2021.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2024101711285632000_8.2.00642-2021.48","doi-asserted-by":"crossref","unstructured":"The REMAP-CAP Investigators , Derde LPG . Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021; preprint [https:\/\/doi.org\/10.1101\/2021.06.18.21259133].","DOI":"10.1101\/2021.06.18.21259133"},{"key":"2024101711285632000_8.2.00642-2021.49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17022"},{"key":"2024101711285632000_8.2.00642-2021.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2024101711285632000_8.2.00642-2021.51","doi-asserted-by":"crossref","unstructured":"Havers FP , Pham H , Taylor CA , et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults \u226518\u2005years \u2013 COVID NET, 13 states, January 1 \u2013 July 24. medRxiv 2021; preprint [https:\/\/doi.org\/10.1101\/2021.08.27.21262356].","DOI":"10.1101\/2021.08.27.21262356"},{"key":"2024101711285632000_8.2.00642-2021.52","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.53","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2213-2600(21)00456-2","article-title":"Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers","volume":"9","author":"Tober-Lau","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.54","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMc2112981","article-title":"Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce","volume":"385","author":"Keehner","year":"2021","journal-title":"N Engl J Med"},{"key":"2024101711285632000_8.2.00642-2021.55","doi-asserted-by":"crossref","unstructured":"Patalon T , Gazit S , Pitzer VE , et al. Short term reduction in the odds of testing positive for SARS-CoV-2; a comparison between two doses and three doses of the BNT162b2 vaccine. medRxiv 2021; preprint [https:\/\/doi.org\/10.1101\/2021.08.29.21262792].","DOI":"10.1101\/2021.08.29.21262792"},{"key":"2024101711285632000_8.2.00642-2021.56","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702090"},{"key":"2024101711285632000_8.2.00642-2021.58","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.vaccine.2019.09.061","article-title":"Vaccination of healthcare personnel in Europe: update to current policies","volume":"37","author":"Maltezou","year":"2019","journal-title":"Vaccine"},{"key":"2024101711285632000_8.2.00642-2021.59","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix549"},{"key":"2024101711285632000_8.2.00642-2021.60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.chest.2021.04.002","article-title":"Hospital-acquired infections in critically ill patients with COVID-19","volume":"160","author":"Grasselli","year":"2021","journal-title":"Chest"},{"key":"2024101711285632000_8.2.00642-2021.61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Task force report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"Verweij","year":"2021","journal-title":"Intensive Care Med"},{"key":"2024101711285632000_8.2.00642-2021.62","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00135-20"},{"key":"2024101711285632000_8.2.00642-2021.63","doi-asserted-by":"crossref","first-page":"e0016321","DOI":"10.1128\/Spectrum.00163-21","article-title":"Coinfections with other respiratory pathogens among patients with COVID-19","volume":"9","author":"Sreenath","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2024101711285632000_8.2.00642-2021.64","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s10096-021-04213-6","article-title":"Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit","volume":"40","author":"Maataoui","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024101711285632000_8.2.00642-2021.65","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp13X669185"},{"key":"2024101711285632000_8.2.00642-2021.66","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s40273-021-01054-1","article-title":"Economic analyses of respiratory tract infection diagnostics: a systematic review","volume":"39","author":"van der Pol","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"2024101711285632000_8.2.00642-2021.67","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.68","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/QCO.0000000000000539","article-title":"Monoclonal antibody-based therapies for bacterial infections","volume":"32","author":"Motley","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"2024101711285632000_8.2.00642-2021.69","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5229-2"},{"key":"2024101711285632000_8.2.00642-2021.70","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1007\/s00253-021-11488-4","article-title":"Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections","volume":"105","author":"Parray","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024101711285632000_8.2.00642-2021.71","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00579-20"},{"key":"2024101711285632000_8.2.00642-2021.72","doi-asserted-by":"crossref","first-page":"100088","DOI":"10.1016\/j.clinpr.2021.100088","article-title":"Recombinant human plasma gelsolin (rhu-pGSN) in a patient hospitalized with critical COVID-19 pneumonia","volume":"12","author":"Catteeuw","year":"2021","journal-title":"Clin Infect Pract"},{"key":"2024101711285632000_8.2.00642-2021.73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136577"},{"key":"2024101711285632000_8.2.00642-2021.74","unstructured":"Cystic Fibrosis Foundation Patient Registry . 2019 Annual Data Report. Bethesda, Cystic Fibrosis Foundation, 2020."},{"key":"2024101711285632000_8.2.00642-2021.75","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204000"},{"key":"2024101711285632000_8.2.00642-2021.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.04.006"},{"key":"2024101711285632000_8.2.00642-2021.77","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22917"},{"key":"2024101711285632000_8.2.00642-2021.78","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2021.05.001","article-title":"Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis","volume":"20","author":"Westh\u00f6lter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024101711285632000_8.2.00642-2021.79","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.chest.2017.01.019","article-title":"Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 <30% of predicted in the United States","volume":"151","author":"Ramos","year":"2017","journal-title":"Chest"},{"key":"2024101711285632000_8.2.00642-2021.80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1008"},{"key":"2024101711285632000_8.2.00642-2021.81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00224-2019"},{"key":"2024101711285632000_8.2.00642-2021.82","unstructured":"WHO . WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2019."},{"key":"2024101711285632000_8.2.00642-2021.83","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01449-2018"},{"key":"2024101711285632000_8.2.00642-2021.84","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30531-X"},{"key":"2024101711285632000_8.2.00642-2021.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.12.016"},{"key":"2024101711285632000_8.2.00642-2021.86","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0823-1"},{"key":"2024101711285632000_8.2.00642-2021.87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/cid\/cix274","article-title":"Long-term outcome of pulmonary resection for nontuberculous mycobacterial pulmonary disease","volume":"65","author":"Asakura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024101711285632000_8.2.00642-2021.88","doi-asserted-by":"crossref","first-page":"P949","DOI":"10.1016\/j.athoracsur.2021.03.088","article-title":"Outcomes of surgical treatment for Mycobacterium abscessus complex pulmonary disease","volume":"113","author":"Togo","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2024101711285632000_8.2.00642-2021.89","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008\u20132015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024101711285632000_8.2.00642-2021.90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12890-019-0901-z","article-title":"Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: a nationwide population-based study","volume":"19","author":"Park","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2024101711285632000_8.2.00642-2021.91","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_18_19"},{"key":"2024101711285632000_8.2.00642-2021.92","doi-asserted-by":"crossref","first-page":"139796","DOI":"10.1016\/j.scitotenv.2020.139796","article-title":"Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001-2016","volume":"740","author":"Thomson","year":"2020","journal-title":"Sci Total Environ"},{"key":"2024101711285632000_8.2.00642-2021.93","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.64"},{"key":"2024101711285632000_8.2.00642-2021.94","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1125"},{"key":"2024101711285632000_8.2.00642-2021.95","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2024101711285632000_8.2.00642-2021.96","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rmed.2019.10.006","article-title":"Efficacy and safety of tigecycline for Mycobacterium abscessus disease","volume":"158","author":"Kwon","year":"2019","journal-title":"Respir Med"},{"key":"2024101711285632000_8.2.00642-2021.97","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01505-12"},{"key":"2024101711285632000_8.2.00642-2021.98","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02349-19"},{"key":"2024101711285632000_8.2.00642-2021.99","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0543"},{"key":"2024101711285632000_8.2.00642-2021.100","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz511"},{"key":"2024101711285632000_8.2.00642-2021.101","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01915-18"},{"key":"2024101711285632000_8.2.00642-2021.102","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02234-18"},{"key":"2024101711285632000_8.2.00642-2021.103","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02613-18"},{"key":"2024101711285632000_8.2.00642-2021.104","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00665-19"},{"key":"2024101711285632000_8.2.00642-2021.105","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2764"},{"key":"2024101711285632000_8.2.00642-2021.106","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"2024101711285632000_8.2.00642-2021.107","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0700OC"},{"key":"2024101711285632000_8.2.00642-2021.108","doi-asserted-by":"crossref","first-page":"ofy034","DOI":"10.1093\/ofid\/ofy034","article-title":"Positive effect of liposomal amikacin for inhalation on Mycobacterium abcessus in cystic fibrosis patients","volume":"5","author":"Caimmi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024101711285632000_8.2.00642-2021.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.05.013"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00642-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:14:01Z","timestamp":1740374041000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00642-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":109,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1183\/23120541.00642-2021"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00642-2021","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}